Novartis AG (NVS, Financials) has received a sobering reminder of how quickly billions of dollars in prospective medicine sales can disappear. Its experimental cholesterol drug pelacarsen failed in a high-profile late-stage study.
But the medicine failed to provide the hoped-for reduction in major cardiovascular events. That’s important because expectations were sky-high
If effective, analysts had predicted the treatment might one day produce yearly sales of $3 billion to $6 billion. That chance now looks much less plausible.
There is always that danger in drug development. One trial can transform the whole financial picture for a treatment after years of research and hundreds of millions of dollars. Novartis is big enough to take a clinical failure.
But the loss of a possible multibillion-dollar product means the remainder of its pipeline has to produce for future development. That is what investors will be looking at next.
The question is no longer what pelacarsen could have been. It’s the late-stage Novartis medication that delivers the growth investors were hoping for.